TRAPPC9

TRAPPC9 is a TRAPPII complex subunit that integrates vesicle trafficking with NF-κB signaling and is essential for normal brain development. Within the TRAPPII complex, TRAPPC9 is recruited via TRAPPC2 acting as an adaptor and in turn binds TRAPPC10; at the ERGIC membrane, TRAPPC9 directly binds the dynactin subunit p150(Glued), competitively uncoupling it from COPII coat proteins Sec23/Sec24 to relay vesicle–dynactin interactions during ER-to-Golgi transport (PMID:21858081, PMID:22279557). TRAPPC9 also functions as a Rab11 GEF activator required for endocytic receptor recycling in neurons, and it potentiates TNF-α–induced NF-κB signaling by binding phosphorylated IKKβ to enhance IKK complex activation (PMID:33208359, PMID:15951441, PMID:25704885). Biallelic loss-of-function mutations in TRAPPC9 cause autosomal-recessive intellectual disability with postnatal microcephaly, obesity, and congenital disorder of glycosylation type I–like N-glycosylation defects; TRAPPC9 is predominantly expressed from the maternally inherited allele owing to genomic imprinting (PMID:20004763, PMID:32877400, PMID:35042660).

1. 2005 High

   Establishing that TRAPPC9 participates in NF-κB signaling answered whether this uncharacterized protein had a role in inflammatory signal transduction: TRAPPC9 physically binds NIK and IKKβ and is required for TNF-α–induced NF-κB activation and NGF-driven neuronal differentiation.

   Evidence Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, and NF-κB reporter assays in PC12 cells

   PMID:15951441

   Open questions at the time

   • Mechanism by which TRAPPC9 enhances IKK phosphorylation was unresolved
   • Relationship to vesicle trafficking machinery not yet examined
   • In vivo neuronal requirement not tested
2. 2009 High

   Identifying TRAPPC9 truncating mutations in families with intellectual disability and microcephaly established TRAPPC9 as essential for human brain development, linking its NF-κB and trafficking functions to a Mendelian disorder.

   Evidence Homozygosity mapping, nonsense mutation identification, expression analysis, and brain MRI in two independent consanguineous families

   PMID:20004763 PMID:20004765

   Open questions at the time

   • Animal model to recapitulate human phenotype not yet available
   • Cellular mechanism underlying microcephaly unknown
   • Whether trafficking or NF-κB function drives pathology was unclear
3. 2011 High

   Demonstrating that TRAPPC2 acts as an adaptor bridging TRAPPC9 to the core TRAPP complex, and that disease-causing mutations in either TRAPPC2 or TRAPPC9 disrupt this interaction, defined the assembly hierarchy of mammalian TRAPPII.

   Evidence Co-immunoprecipitation with domain-deletion and disease-mutant analysis in mammalian cells

   PMID:21858081

   Open questions at the time

   • Stoichiometry and structural details of the TRAPPII assembly not resolved
   • Whether TRAPPC9-TRAPPC10 interaction is direct or TRAPPC2-dependent was not fully clarified
4. 2012 High

   Showing that TRAPPC9 directly binds p150(Glued) and competitively displaces COPII coat subunits from dynactin answered how TRAPPII relays vesicle identity at the ERGIC membrane during ER-to-Golgi transport.

   Evidence In vitro binding assays, co-immunoprecipitation, and overexpression competition experiments

   PMID:22279557

   Open questions at the time

   • Functional consequence of disrupting this handoff on cargo delivery not measured in vivo
   • Whether this mechanism operates in neurons specifically was untested
5. 2015 High

   Demonstrating that endogenous TRAPPC9 binds specifically to phosphorylated IKKβ in a TNF-α–dependent manner refined the mechanism of NF-κB potentiation and connected elevated TRAPPC9 to oncogenic signaling.

   Evidence Co-immunoprecipitation of endogenous phospho-IKK2, NF-κB reporter, shRNA knockdown, and xenograft tumorigenesis assay in breast/colon cancer cells

   PMID:25704885

   Open questions at the time

   • Structural basis for phospho-IKKβ selectivity unknown
   • Whether the NF-κB and trafficking functions of TRAPPC9 are separable was not addressed
6. 2020 High

   Trappc9 knockout mice established that TRAPPC9 is a Rab11 GEF activator required for endocytic receptor recycling in neurons, directly linking TRAPPII trafficking function to the microcephaly/obesity phenotype and revealing an imprinting effect with predominant maternal-allele expression.

   Evidence Trappc9 KO mice with Rab11 activation assays, endocytic recycling assays in neurons, behavioral phenotyping, allele-specific expression analysis, and pharmacological rescue

   PMID:32877400 PMID:33208359

   Open questions at the time

   • Whether Rab11 activation defect fully accounts for microcephaly or other GEFs compensate
   • Imprinting mechanism (epigenetic marks at the locus) not characterized
   • Relative contributions of NF-κB versus Rab11 dysfunction to neuronal pathology unresolved
7. 2022 High

   Showing that TRAPPC9 deficiency causes CDG-I–like N-glycosylation defects, rescuable by wild-type complementation, expanded the functional repertoire beyond vesicle trafficking to glycosylation homeostasis.

   Evidence N-glycosylation analysis and tracer metabolomics in patient fibroblasts with biallelic TRAPPC9 variants, complementation rescue

   PMID:35042660

   Open questions at the time

   • Whether glycosylation defects are secondary to Golgi trafficking disruption or reflect an independent TRAPPC9 function is unresolved
   • Impact of glycosylation defects on neuronal function not examined

• Key open questions remain: whether the NF-κB–potentiating and Rab11 GEF/trafficking functions of TRAPPC9 are structurally and functionally separable, what the structural basis of TRAPPII assembly and substrate specificity is, and how TRAPPC9 imprinting is regulated at the epigenetic level.
• No high-resolution structure of mammalian TRAPPII including TRAPPC9
• Separation-of-function alleles distinguishing NF-κB from trafficking roles not generated
• Epigenetic regulation of TRAPPC9 imprinting not characterized